Traws Pharma, Inc. (TRAW)

From the record

Traws Pharma, Inc.'s filings since 2017 show 23 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 19 times, the latest 2026-07-31); an auditor change (8-K item 4.01, 2 times, the latest 2024-07-19); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2026-03-31) (its current reports).

From the record

Traws Pharma, Inc.'s 10 filed years say what it did: revenue went from $6 million in fiscal 2016 to $3 million in fiscal 2025, down 7.4% a year; it rose in 6 of 9 years; the deepest fall was 96% from fiscal 2016 to fiscal 2021; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Traws Pharma, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 106 cents per dollar of assets, and net share issuance: its share count grew 439.5% over the year (the filed statements).

From the record

Traws Pharma, Inc.'s standing among 315 graded names in its industry family: revenue of $3 million in fiscal 2025 ranks in the bottom 30% by size; a net margin of 328.7% ranks in the top 2%; revenue growth of 131.1% a year over the last 3 filed years ranks in the top 10% (its annual reports).

From the record

Traws Pharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dukes, Iain D. (Chief Executive Officer, as filed), filing under that title since 2025-10-15, 1.1 years (bottom 16% of its family); most of the 10 officers and directors filing now have filed since the record of its people begins (2024-04-01), a floor of 2.6 years the record cannot see past, so that part is not read; 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Traws Pharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 36% of its assets as net cash, top 41% of its family; cash from operations less capital spending is -744.4% of revenue (bottom 29%); research spending of 435.2% of revenue (top 30%) (its annual report).

From the record

Traws Pharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 131.1% a year over the last three filed years against -7.4% over all 10, speeding up (top 3% of its family); the newest year grew 1136.6% (top 4%); research spending grew 3.1% a year (top 48%); capital spending grew -29.2% a year (bottom 38%) (its annual reports). Traws Pharma, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Traws Pharma, Inc.'s newest year against its own record: revenue of $3 million in fiscal 2025 came in 1134.5% above the $226 thousand its prior three years' pace pointed to (top 5% of its family); net income of $9 million against a prior three-year average of $68 million (top 14%); a net margin of more than its whole revenue against losses larger than its revenue before (top 3%) (its annual reports).